Drug intelligence / Profile preview

HDM1702

Development stage: Phase 3
Lead developer: Hangzhou Zhongmei Huadong Pharmaceutical
Modality: Peptides
Administration: Injection

Overview

HDM1702 is an investigational drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It is a biosimilar of semaglutide, currently undergoing a Phase III clinical study for the treatment of obesity. The drug is administered as a once-weekly injection, following a fixed-dose escalation regimen to reach a maintenance dose of 2.4 mg.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on HDM1702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM1702.

Explore the full profile